SC
NMRA icon

Steven Cohen’s Neumora Therapeutics NMRA Stock Holding History

Steven Cohen’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-602,403
Closed -$1.17M – 4412
2026
Q1 		$1.17M Sell
602,403
-3,071,436
-84% -$7.96M ﹤0.01% 2665
2025
Q4 		$6.58M Buy
+3,673,839
New +$8.04M 0.01% 1629
2024
Q4 		– Sell
-83,077
Closed -$996K – 2325
2024
Q3 		$1.1M Buy
+83,077
New +$969K ﹤0.01% 1379

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steven Cohen's NMRA Position: Q2 2026 in Review

Steven Cohen sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 602,403 shares — an estimated $1.17M sold.

Steven Cohen first reported a position in NMRA in Q3 2024 and held it in 3 quarters. The position peaked at $6.58M in Q4 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Steven Cohen reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 602,403 Neumora Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Steven Cohen first reported a position in Neumora Therapeutics in Q3 2024 and held it in 3 quarters.
  • Steven Cohen's Neumora Therapeutics position peaked at $6.58M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.